A flagship of British biotechnology disappeared from view on 29 October when Cambridge Antibody Technology (CAT) was merged into MedImmune in Gaithersburg, Maryland. MedImmune is being developed into the biologicals arm of AstraZeneca, the pharmaceutical giant that bought it in April for $15.6 billion. CAT, which was founded in 1990 and made its name developing antibody therapies, was acquired by AstraZeneca in 2006. CAT's operations will continue, as part of MedImmune.